Celgene will add as much as $1.25 billion to the upfront payment if Impact’s drug fedratinib reaches approval milestones to treat myelofibrosis, a form of bone marrow cancer, and
another $150 million for other indications. Additional payments could reach as much as $4.5 billion if global annual sales rise above $5 billion.Read the whole story at Bloomberg »
